Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and decitabine in secondary AML (ENABLE)
NCT04763928Phase 2Active, not recruiting
- Sponsor
- GIMEMA
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by GIMEMA. Primary endpoint: Event-Free Survival at 1 year. Started Dec 2021; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04763928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04763928.